RBC Capital initiated coverage of Krystal Biotech (KRYS) on Friday. The firm issued an Outperform rating. Analysts set a price target of $400 for the stock.
The company reported second-quarter 2026 financial results in August. Its primary product, VYJUVEK, generated significant revenue during the period.